Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 9 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Loading...
